Explore a selection of our essential drug information below, or:
Overview
- Description
- A medication used to treat lead poisoning.
- Description
- A medication used to treat lead poisoning.
- DrugBank ID
- DB14598
- Type
- Small Molecule
- Clinical Trials
- Phase 0
- 0
- Phase 1
- 2
- Phase 2
- 1
- Phase 3
- 1
- Phase 4
- 1
- Mechanism of Action
- LeadChelator
- IronChelator
- Manganese cationChelator
- Lead
Identification
- Summary
Edetate calcium disodium is a chelating agent used to treat lead poisoning.
- Brand Names
- Calcium Disodium Versenate
- Generic Name
- Edetate calcium disodium anhydrous
Commonly known or available as Edetate calcium disodium - DrugBank Accession Number
- DB14598
- Background
Edetate calcium disodium is a metal ion chelator used to reduce blood concentrations and depot stores of lead from the body.7 It is on the World Health Organization Model List of Essential Medicines.5
Edetate calcium disodium was granted FDA approval on 16 July 1953.7
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Edetate calcium disodium anhydrous (DB14598)
- Weight
- Average: 374.268
Monoisotopic: 374.001495875 - Chemical Formula
- C10H12CaN2Na2O8
- Synonyms
- Edetate calcium disodium (anhydrous)
- Edetic acid calcium disodium salt
Pharmacology
- Indication
Edetate calcium disodium is indicated to reduce blood levels and depot stores of lead in acute and chronic lead poisoning.7
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Adjunct therapy in treatment of Poisoning, lead •••••••••••• •••••• ••••••••• ••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Edetate calcium disodium is a polyvalent ion chelator used to remove lead from the body after lead poisoning.7 It has a wide therapeutic index, as overdoses must be well in excess of the therapeutic dose to show symptoms.7 It has a long duration of action, as doses are given at least a day apart.7 Patients should be counselled regarding the risk of increased intracranial pressure with intravenous infusions.7
- Mechanism of action
Edetate calcium disodium distributes into tissues, such as the kidney and bone, where it chelates lead ions.1,3 The lead ions are then eliminated in the normal urinary excretion of edetate.1,2 Lead in certain tissues such as the liver and bone, redistribute to other tissues after edetate calcium disodium treatment, but lead levels do not decrease to levels seen in unexposed patients.2
Target Actions Organism ALead chelatorHumans AIron chelatorHumans AManganese cation chelatorHumans - Absorption
Calcium edetate disodium's Cmax and AUC are dependant on renal function.4 5% of an oral dose is absorbed from the gastrointestinal tract.6
- Volume of distribution
The volume of distribution of edetate calcium disodium is 0.19±0.10L/kg.3
- Protein binding
Not Available
- Metabolism
Edetate calcium disodium is almost completely unmetabolized in vivo.6,7
- Route of elimination
Edetate calcium disodium is 95% eliminated in the urine within 24 hours.3,7 An oral dose in rats was 88.32% recovered in the feces and 10.30% recovered in the urine.6
- Half-life
The half life of edetate calcium disodium is 20-60 minutes.7
- Clearance
The mean clearance of edetate in 1 month olds is 54.6mL/min/1.73m2.6 2-17 year olds have a mean clearance of 113.9±24.4mL/min/1.73m2.6
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Patients experiencing an overdose may present with similar symptoms to severe lead poisoning such as cerebral edema and renal tubular necrosis.7 Overdose can be managed through the administration of mannitol, zinc level monitoring, and maintenance of urinary output.7
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareTechnetium Tc-99m oxidronate Edetate calcium disodium anhydrous may decrease effectiveness of Technetium Tc-99m oxidronate as a diagnostic agent. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Edetate calcium disodium 25IH6R4SGF 6766-87-6 JCQNARRMQCMKAN-UHFFFAOYSA-J - Active Moieties
Name Kind UNII CAS InChI Key Edetic acid unknown 9G34HU7RV0 60-00-4 KCXVZYZYPLLWCC-UHFFFAOYSA-N - Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Calcium Disodium Versenate Injection 200 mg/1mL Intramuscular Graceway Pharmaceuticals 2009-07-09 2007-09-19 US 
Calcium Disodium Versenate Injection 200 mg/1mL Intramuscular 3 M Pharmaceuticals 2009-07-09 2015-12-31 US Calcium Disodium Versenate Injection 200 mg/1mL Intramuscular; Intravenous Bausch Health, Canada Inc. 2013-06-21 Not applicable US Calcium Disodium Versenate Injection 200 mg/1mL Intramuscular Graceway Pharmaceuticals 2009-07-09 2015-12-31 US Calcium Disodium Versenate Liq 200mg/ml Liquid 200 mg / mL Intramuscular; Intravenous; Subcutaneous 3 M Pharmaceuticals, A Division Of 3 M Canada Company 1993-12-31 2006-07-24 Canada 
- Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Edetate Calcium Disodium Injection 200 mg/1mL Intramuscular; Intravenous Rising Pharma Holdings, Inc. 2023-05-03 Not applicable US Edetate Calcium Disodium Injection 200 mg/1mL Intramuscular; Intravenous Casper Pharma Llc 2023-05-03 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Calcium Edetate de Sodium Edetate calcium disodium anhydrous (50 mg/1mL) Solution Intravenous BTG International Inc. 2022-10-21 2024-07-31 US
Categories
- Drug Categories
- Acetates
- Acids, Acyclic
- Amines
- Anticoagulants
- Calcium Chelating Activity
- Calcium Chelating Agents
- Chelating Activity
- Chelating Agents
- Compounds used in a research, industrial, or household setting
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors (strength unknown)
- Cytochrome P-450 Enzyme Inhibitors
- Diamines
- Diet, Food, and Nutrition
- Ethylenediamines
- Food
- Food Additives
- Food Ingredients
- Hematologic Agents
- Iron Chelating Activity
- Iron Chelating Agents
- Lead Chelating Activity
- Lead Chelator
- Metal Chelating Activity
- Metal Chelator
- Physiological Phenomena
- Polyamines
- Sequestering Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as tetracarboxylic acids and derivatives. These are carboxylic acids containing exactly four carboxyl groups.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Tetracarboxylic acids and derivatives
- Direct Parent
- Tetracarboxylic acids and derivatives
- Alternative Parents
- Alpha amino acids / Trialkylamines / Carboxylic acid salts / Amino acids / Organic calcium salts / Carboxylic acids / Organopnictogen compounds / Organic zwitterions / Organic sodium salts / Organic oxides show 2 more
- Substituents
- Aliphatic acyclic compound / Alpha-amino acid / Alpha-amino acid or derivatives / Amine / Amino acid / Amino acid or derivatives / Carbonyl group / Carboxylic acid / Carboxylic acid salt / Hydrocarbon derivative show 14 more
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 8U5D034955
- CAS number
- 62-33-9
- InChI Key
- SHWNNYZBHZIQQV-UHFFFAOYSA-J
- InChI
- InChI=1S/C10H16N2O8.Ca.2Na/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20;;;/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20);;;/q;+2;2*+1/p-4
- IUPAC Name
- calcium disodium 2-({2-[bis(carboxymethyl)amino]ethyl}(carboxymethyl)amino)acetate
- SMILES
- [Na+].[Na+].[Ca++].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O
References
- General References
- Hammond PB, Aronson AL, Olson WC: The mechanism of mobilization of lead by ethylenediaminetetraacetate. J Pharmacol Exp Ther. 1967 Jul;157(1):196-206. [Article]
- Cory-Slechta DA, Weiss B, Cox C: Mobilization and redistribution of lead over the course of calcium disodium ethylenediamine tetraacetate chelation therapy. J Pharmacol Exp Ther. 1987 Dec;243(3):804-13. [Article]
- Bradberry S, Vale A: A comparison of sodium calcium edetate (edetate calcium disodium) and succimer (DMSA) in the treatment of inorganic lead poisoning. Clin Toxicol (Phila). 2009 Nov;47(9):841-58. doi: 10.3109/15563650903321064. [Article]
- Osterloh J, Becker CE: Pharmacokinetics of CaNa2EDTA and chelation of lead in renal failure. Clin Pharmacol Ther. 1986 Dec;40(6):686-93. doi: 10.1038/clpt.1986.245. [Article]
- Sakthithasan K, Levy P, Poupon J, Garnier R: A comparative study of edetate calcium disodium and dimercaptosuccinic acid in the treatment of lead poisoning in adults. Clin Toxicol (Phila). 2018 Nov;56(11):1143-1149. doi: 10.1080/15563650.2018.1478424. Epub 2018 Jun 11. [Article]
- Lanigan RS, Yamarik TA: Final report on the safety assessment of EDTA, calcium disodium EDTA, diammonium EDTA, dipotassium EDTA, disodium EDTA, TEA-EDTA, tetrasodium EDTA, tripotassium EDTA, trisodium EDTA, HEDTA, and trisodium HEDTA. Int J Toxicol. 2002;21 Suppl 2:95-142. doi: 10.1080/10915810290096522. [Article]
- FDA Approved Drug Products: Edetate Calcium Disodium Intravenous or Intramuscular Injection [Link]
- External Links
- Human Metabolome Database
- HMDB0301765
- PubChem Compound
- 6109
- ChemSpider
- 5883
- ChEBI
- 4757
- ChEMBL
- CHEMBL1200375
- Wikipedia
- Sodium_calcium_edetate
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection Intramuscular 200 mg/1mL Injection Intramuscular; Intravenous 200 mg/1mL Liquid Intramuscular; Intravenous; Subcutaneous 200 mg / mL Solution Intravenous 50 mg/1mL Solution Intramuscular; Intravenous 200 mg Injection, solution Intramuscular; Intravenous Injection, solution Intramuscular; Intravenous 400 mg/2ml Solution Intramuscular; Intravenous 200 mg/1ml - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) >300 Budavari, 1989 - Predicted Properties
Property Value Source Water Solubility 23.1 mg/mL ALOGPS logP 0.03 ALOGPS logP -4.9 Chemaxon logS -1.3 ALOGPS pKa (Strongest Acidic) 2.35 Chemaxon pKa (Strongest Basic) 7.73 Chemaxon Physiological Charge -3 Chemaxon Hydrogen Acceptor Count 10 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 167 Å2 Chemaxon Rotatable Bond Count 11 Chemaxon Refractivity 105.69 m3·mol-1 Chemaxon Polarizability 24.74 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 160.62097 predictedDeepCCS 1.0 (2019) [M+H]+ 163.0977 predictedDeepCCS 1.0 (2019) [M+Na]+ 170.9228 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Yes
Chelator
References
- Onnby L, Giorgi C, Plieva FM, Mattiasson B: Removal of heavy metals from water effluents using supermacroporous metal chelating cryogels. Biotechnol Prog. 2010 Sep-Oct;26(5):1295-302. doi: 10.1002/btpr.422. [Article]
- Chakraborty N, Banerjee A, Pal R: Accumulation of lead by free and immobilized cyanobacteria with special reference to accumulation factor and recovery. Bioresour Technol. 2011 Mar;102(5):4191-5. doi: 10.1016/j.biortech.2010.12.028. Epub 2010 Dec 13. [Article]
- Tian SK, Lu LL, Yang XE, Huang HG, Brown P, Labavitch J, Liao HB, He ZL: The impact of EDTA on lead distribution and speciation in the accumulator Sedum alfredii by synchrotron X-ray investigation. Environ Pollut. 2011 Mar;159(3):782-8. doi: 10.1016/j.envpol.2010.11.020. Epub 2010 Dec 18. [Article]
Yes
Chelator
References
- Hasegawa H, Rahman IM, Kinoshita S, Maki T, Furusho Y: Separation of dissolved iron from the aqueous system with excess ligand. Chemosphere. 2011 Feb;82(8):1161-7. doi: 10.1016/j.chemosphere.2010.12.048. Epub 2011 Jan 3. [Article]
Yes
Chelator
References
- Broncel M, Wagner SC, Paul K, Hackenberger CP, Koksch B: Towards understanding secondary structure transitions: phosphorylation and metal coordination in model peptides. Org Biomol Chem. 2010 Jun 7;8(11):2575-9. doi: 10.1039/c001458c. Epub 2010 Mar 29. [Article]
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Catalyzes the hydrolytic deamination of adenosine and 2-deoxyadenosine (PubMed:16670267, PubMed:23193172, PubMed:26166670, PubMed:8452534, PubMed:9361033). Plays an important role in purine metabolism and in adenosine homeostasis. Modulates signaling by extracellular adenosine, and so contributes indirectly to cellular signaling events. Acts as a positive regulator of T-cell coactivation, by binding DPP4 (PubMed:20959412). Its interaction with DPP4 regulates lymphocyte-epithelial cell adhesion (PubMed:11772392). Enhances dendritic cell immunogenicity by affecting dendritic cell costimulatory molecule expression and cytokines and chemokines secretion (By similarity). Enhances CD4+ T-cell differentiation and proliferation (PubMed:20959412). Acts as a positive modulator of adenosine receptors ADORA1 and ADORA2A, by enhancing their ligand affinity via conformational change (PubMed:23193172). Stimulates plasminogen activation (PubMed:15016824). Plays a role in male fertility (PubMed:21919946, PubMed:26166670). Plays a protective role in early postimplantation embryonic development (By similarity). Also responsible for the deamination of cordycepin (3'-deoxyadenosine), a fungal natural product that shows antitumor, antibacterial, antifungal, antivirus, and immune regulation properties (PubMed:26038697)
- Specific Function
- 2'-deoxyadenosine deaminase activity
- Gene Name
- ADA
- Uniprot ID
- P00813
- Uniprot Name
- Adenosine deaminase
- Molecular Weight
- 40764.13 Da
References
- Abu-Shady MR, Elshafei AM, el-Beih FM, Mohamed LA: Properties of adenosine deaminase in extracts of Asperigillus terricola. Acta Microbiol Pol. 1994;43(3-4):305-11. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Has low activity towards the organophosphate paraxon and aromatic carboxylic acid esters. Rapidly hydrolyzes lactones such as statin prodrugs (e.g. lovastatin). Hydrolyzes aromatic lactones and 5- or 6-member ring lactones with aliphatic substituents but not simple lactones or those with polar substituents
- Specific Function
- acyl-L-homoserine-lactone lactonohydrolase activity
- Gene Name
- PON3
- Uniprot ID
- Q15166
- Uniprot Name
- Serum paraoxonase/lactonase 3
- Molecular Weight
- 39607.185 Da
References
- Pla A, Rodrigo L, Hernandez AF, Gil F, Lopez O: Effect of metal ions and calcium on purified PON1 and PON3 from rat liver. Chem Biol Interact. 2007 Apr 5;167(1):63-70. Epub 2007 Jan 16. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Modulator
- General Function
- A cytochrome P450 monooxygenase that catalyzes the conversion of C19 androgens, androst-4-ene-3,17-dione (androstenedione) and testosterone to the C18 estrogens, estrone and estradiol, respectively (PubMed:27702664, PubMed:2848247). Catalyzes three successive oxidations of C19 androgens: two conventional oxidations at C19 yielding 19-hydroxy and 19-oxo/19-aldehyde derivatives, followed by a third oxidative aromatization step that involves C1-beta hydrogen abstraction combined with cleavage of the C10-C19 bond to yield a phenolic A ring and formic acid (PubMed:20385561). Alternatively, the third oxidative reaction yields a 19-norsteroid and formic acid. Converts dihydrotestosterone to delta1,10-dehydro 19-nordihydrotestosterone and may play a role in homeostasis of this potent androgen (PubMed:22773874). Also displays 2-hydroxylase activity toward estrone (PubMed:22773874). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) (PubMed:20385561, PubMed:22773874)
- Specific Function
- aromatase activity
- Gene Name
- CYP19A1
- Uniprot ID
- P11511
- Uniprot Name
- Aromatase
- Molecular Weight
- 57882.48 Da
References
- Moslemi S, Vibet A, Papadopoulos V, Camoin L, Silberzahn P, Gaillard JL: Purification and characterization of equine testicular cytochrome P-450 aromatase: comparison with the human enzyme. Comp Biochem Physiol B Biochem Mol Biol. 1997 Sep;118(1):217-27. [Article]
- Bellino FL, Holben L: Placental estrogen synthetase (aromatase): evidence for phosphatase-dependent inactivation. Biochem Biophys Res Commun. 1989 Jul 14;162(1):498-504. [Article]
- Zhang F, Zhou D, Kao YC, Ye J, Chen S: Expression and purification of a recombinant form of human aromatase from Escherichia coli. Biochem Pharmacol. 2002 Nov 1;64(9):1317-24. [Article]
- Milczarek R, Sokolowska E, Hallmann A, Kaletha K, Klimek J: NADPH- and iron-dependent lipid peroxidation inhibit aromatase activity in human placental microsomes. J Steroid Biochem Mol Biol. 2008 Jun;110(3-5):230-5. doi: 10.1016/j.jsbmb.2007.11.004. Epub 2008 Apr 20. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- A cytochrome P450 monooxygenase involved in the metabolism of sterols, steroid hormones, retinoids and fatty acids (PubMed:10681376, PubMed:11093772, PubMed:11555828, PubMed:12865317, PubMed:14559847, PubMed:15373842, PubMed:15764715, PubMed:19965576, PubMed:20702771, PubMed:21490593, PubMed:21576599). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the hydroxylation of carbon-hydrogen bonds (PubMed:12865317, PubMed:14559847, PubMed:15373842, PubMed:15764715, PubMed:21490593, PubMed:21576599, PubMed:2732228). Exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta-estradiol (E2), namely 2-hydroxy E1 and E2, as well as D-ring hydroxylated E1 and E2 at the C-16 position (PubMed:11555828, PubMed:12865317, PubMed:14559847). Plays a role in the metabolism of androgens, particularly in oxidative deactivation of testosterone (PubMed:15373842, PubMed:15764715, PubMed:22773874, PubMed:2732228). Metabolizes testosterone to less biologically active 2beta- and 6beta-hydroxytestosterones (PubMed:15373842, PubMed:15764715, PubMed:2732228). Contributes to the formation of hydroxycholesterols (oxysterols), particularly A-ring hydroxylated cholesterol at the C-4beta position, and side chain hydroxylated cholesterol at the C-25 position, likely contributing to cholesterol degradation and bile acid biosynthesis (PubMed:21576599). Catalyzes bisallylic hydroxylation of polyunsaturated fatty acids (PUFA) (PubMed:9435160). Catalyzes the epoxidation of double bonds of PUFA with a preference for the last double bond (PubMed:19965576). Metabolizes endocannabinoid arachidonoylethanolamide (anandamide) to 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs), potentially modulating endocannabinoid system signaling (PubMed:20702771). Plays a role in the metabolism of retinoids. Displays high catalytic activity for oxidation of all-trans-retinol to all-trans-retinal, a rate-limiting step for the biosynthesis of all-trans-retinoic acid (atRA) (PubMed:10681376). Further metabolizes atRA toward 4-hydroxyretinoate and may play a role in hepatic atRA clearance (PubMed:11093772). Responsible for oxidative metabolism of xenobiotics. Acts as a 2-exo-monooxygenase for plant lipid 1,8-cineole (eucalyptol) (PubMed:11159812). Metabolizes the majority of the administered drugs. Catalyzes sulfoxidation of the anthelmintics albendazole and fenbendazole (PubMed:10759686). Hydroxylates antimalarial drug quinine (PubMed:8968357). Acts as a 1,4-cineole 2-exo-monooxygenase (PubMed:11695850). Also involved in vitamin D catabolism and calcium homeostasis. Catalyzes the inactivation of the active hormone calcitriol (1-alpha,25-dihydroxyvitamin D(3)) (PubMed:29461981)
- Specific Function
- 1,8-cineole 2-exo-monooxygenase activity
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Bournique B, Petry M, Gousset G: Usefulness of statistic experimental designs in enzymology: example with recombinant hCYP3A4 and 1A2. Anal Biochem. 1999 Dec 1;276(1):18-26. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Hydrolyzes the toxic metabolites of a variety of organophosphorus insecticides. Capable of hydrolyzing a broad spectrum of organophosphate substrates and lactones, and a number of aromatic carboxylic acid esters. Mediates an enzymatic protection of low density lipoproteins against oxidative modification and the consequent series of events leading to atheroma formation
- Specific Function
- acyl-L-homoserine-lactone lactonohydrolase activity
- Gene Name
- PON1
- Uniprot ID
- P27169
- Uniprot Name
- Serum paraoxonase/arylesterase 1
- Molecular Weight
- 39730.99 Da
References
- Pla A, Rodrigo L, Hernandez AF, Gil F, Lopez O: Effect of metal ions and calcium on purified PON1 and PON3 from rat liver. Chem Biol Interact. 2007 Apr 5;167(1):63-70. Epub 2007 Jan 16. [Article]
Drug created at August 25, 2018 15:50 / Updated at November 05, 2024 05:15